Market Overview

UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Celgene Corporation

Share:
Related CELG
Could Rally Cool Off Ahead Of Friday's GDP Data and Yellen Speech?
Celgene Rallies Of Possible Interest From Merck
Gilead and Celgene Among Biotechnology Stocks to Buy (GuruFocus)

In a report published Friday, Citigroup reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $93.00 to $114.00.

Citigroup noted, “Coming out of Q4:12 earnings Celgene's business continues to perform well and we're bullish on the 2013 outlook and see many ways for Celgene to meet/beat ests. We believe Revlimid sales will continue to grow in 2013 and upside to revs and EPS guidance will be bolstered by: 1) strong Abraxane sales given the recent positive pancreatic data; 2) recent Abraxane NSCLC approval; 3) delayed generic Vidaza; and 4) the remaining ~$1.8B in stock buybacks. Celgene is our top idea for lg cap biotech and we expect positive data from the MM-020 study in March/April and that should drive both upwards revs/EPS revisions in 2014 and beyond and multiple expansion. In addition, upcoming apremilast Ph 3 data in psoriasis in Q1:13 and regulatory filing this year should further drive multiple expansion.”

Celgene Corporation closed on Thursday at $97.49.

Latest Ratings for CELG

DateFirmActionFromTo
Apr 2016Credit SuisseMaintainsOutperform
Apr 2016BMO CapitalInitiates Coverage onOutperform
Mar 2016JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!